Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:FDA
2020 |
| gptkbp:ATCCode |
gptkb:L01XC43
|
| gptkbp:combinationTherapy |
gptkb:lenalidomide
|
| gptkbp:developedBy |
gptkb:Incyte
gptkb:MorphoSys |
| gptkbp:genericName |
gptkb:tafasitamab
|
| https://www.w3.org/2000/01/rdf-schema#label |
Monjuvi
|
| gptkbp:indication |
relapsed or refractory diffuse large B-cell lymphoma
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedIn |
gptkb:United_States
|
| gptkbp:mechanismOfAction |
CD19-directed cytolytic antibody
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:anemia
diarrhea edema fatigue cough neutropenia respiratory tract infection pyrexia |
| gptkbp:target |
gptkb:CD19
|
| gptkbp:type |
gptkb:monoclonal_antibody
|
| gptkbp:usedFor |
diffuse large B-cell lymphoma
|
| gptkbp:bfsParent |
gptkb:MorphoSys
|
| gptkbp:bfsLayer |
5
|